PDS Biotechnology Corp
PDSBNasdaq
$0.73
↑ +3.3%Jul 17 close · end-of-day
Price
1Y↓ -39.3%
End-of-day closes; the latest point is the live 15-min-delayed price · split & dividend adjusted · chart by TradingView
Key statistics
Market Cap
$40.8M
Enterprise Value
$19.1M
P/E
—
P/S
—
P/B
10.5
EV/EBITDA
—
PEG
—
FCF Yield
-68.0%
Dividend Yield
—
Revenue (TTM)
—
Net Income (TTM)
-$33.4M
Free Cash Flow (TTM)
-$27.8M
Gross Margin
—
Operating Margin
—
Net Margin
—
ROE
-856.9%
ROIC
—
Debt / Equity
—
Net Cash
$21.7M
Return 1Y
-38.8%
Company profile
PDS Biotechnology Corporation focuses on developing multifunctional cancer immunotherapies. Its lead product candidate is PDS0101 (HPV16), which is in Phase II clinical trial provides a first line treatment for the recurrent/metastatic head and neck cancer, human papillomavirus associated malignancies, and cervical cancer. The company is also developing various product candidates, which are in preclinical trials.
- CEO
- Frank K. Bedu-Addo
- Sector
- Manufacturing
- Industry
- Pharmaceutical Products
- Employees
- 20
- Headquarters
- New Jersey
- Website
- pdsbiotech.com
Earnings
PDSB Q1 2026 Earnings
Period ends 2026-03-31
MetricActualYoY
Revenue——
Diluted EPS-$0.13↓ -38.1%
Actuals from SEC filings; YoY vs the year-ago quarter. Analyst estimates & surprise require a data feed (coming soon).
Financial statements
| Line item | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | — | — |
| Gross profit | — | — | — | — | — | — |
| Operating income | -$14.9M | -$21.4M | -$41.7M | -$43.0M | -$36.3M | -$31.5M |
| Net income | -$14.8M | -$16.9M | -$40.9M | -$42.9M | -$37.6M | -$34.5M |
| Diluted EPS | -$0.89 | -$0.66 | -$1.43 | -$1.39 | -$1.03 | -$0.74 |
| Operating cash flow | -$13.1M | -$12.5M | -$25.7M | -$33.6M | -$35.0M | -$27.8M |
| Free cash flow | — | — | — | -$33.6M | -$35.1M | -$27.8M |
| Gross margin | — | — | — | — | — | — |
| Operating margin | — | — | — | — | — | — |
| Net margin | — | — | — | — | — | — |
| Line item | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 |
|---|---|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | — | — | — | — |
| Gross profit | — | — | — | — | — | — | — | — |
| Operating income | -$8.7M | -$10.2M | -$7.4M | -$9.1M | -$7.6M | -$8.1M | -$6.7M | -$6.5M |
| Net income | -$8.3M | -$10.7M | -$8.0M | -$8.5M | -$9.4M | -$9.0M | -$7.6M | -$7.3M |
| Diluted EPS | -$0.23 | -$0.29 | -$0.21 | -$0.21 | -$0.21 | -$0.19 | -$0.13 | -$0.13 |
| Operating cash flow | -$8.9M | -$8.0M | -$8.2M | -$9.0M | -$9.1M | -$5.9M | -$3.7M | -$4.4M |
| Free cash flow | — | -$8.0M | — | — | — | -$5.9M | — | — |
| Gross margin | — | — | — | — | — | — | — | — |
| Operating margin | — | — | — | — | — | — | — | — |
| Net margin | — | — | — | — | — | — | — | — |
Company news
Jun 10, 2026
May 13, 2026
- 68d agoPDS Biotechnology Corp (PDSB) Q1 2026 Earnings Call Highlights: Strategic Advancements and ...finance.yahoo.com
- 68d agoPDS Biotechnology Q1 Earnings Call Highlightsmarketbeat.com
- 68d agoPDS Biotechnology Corporation Q1 2026 Earnings Call Summaryapp.moby.co
- 68d agoPDS Biotechnology Q1 2026 Earnings Call: Complete Transcriptfinance.yahoo.com
- 68d agoPDS Biotech Reports First Quarter 2026 Financial Results and Provides Clinical Programs and Corporate Updatefinance.yahoo.com
Analyst estimates
Coming soonConsensus revenue & EPS estimates and price targets will appear here once a forward-estimates data feed is connected.
Insider transactions
No insider transactions in the last 12 months.
No insider transactions on file.
Fundamentals & filings from SEC EDGAR. Prices adjusted for splits & dividends. Not investment advice.